ArticleScience signaling2017
Foxo1 and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of T
Open access · greenAbstract read
In one paragraph
Article in Science signaling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 61 citations in OpenAlex.
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of Candidate mRNA and miRNA Molecules Associated with Tuberculosis Through Preliminary Analysis and Validation Using Clinical Samples.International journal of molecular sciences · 2026Article
- Contributions of T-helper 9 cells in endometriosis-associated inflammation and lesion growth.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- A fungi-derived cyclic peptide enhances Th9-mediated antitumor immunity by targeting ZAP70 and SREBP1.The Journal of clinical investigation · 2026Article
- Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes.Journal for immunotherapy of cancer · 2026Article
- Dysregulation of apolipoprotein o reprograms CCR7iScience · 2025Article
- Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications.Molecular biomedicine · 2025Review
- Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis.Scientific reports · 2025Article
- Group 2 innate lymphoid cells derived IL-9 reduces macrophage apoptosis and attenuates acute lung injury in sepsis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Regulatory mechanisms of Th9 cell differentiation.Frontiers in immunology · 2025Review
- Metabolic regulation of Th9 cell differentiation: insights for IL-9-driven diseases.Frontiers in immunology · 2025Review
- Article
- Locus of (IL-9) control: IL9 epigenetic regulation in cellular function and human disease.Experimental & molecular medicine · 2024Review
- Review
- Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma.BMC cancer · 2024Article
- IL-9 promotes methicillin-resistantInfection and immunity · 2023Article
- The Dichotomy of Interleukin-9 Function in the Tumor Microenvironment.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023Review
- Immunotherapy: A new target for cancer cure (Review).Oncology reports · 2023Review
- Lipid peroxidation of immune cells in cancer.Frontiers in immunology · 2023Review
- LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p/FOXP1 axis.Journal of gynecologic oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Enguang BiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.ORCID http://orcid.org/0000-0003-0850-8135
Xingzhe MaDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Yong LuDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Maojie YangDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Qiang WangDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.ORCID http://orcid.org/0000-0002-6141-0068
Gang XueDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Jianfei QianDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Siqing WangDepartment of Cancer Immunology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun 130061, China.
Qing YiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. yiq@ccf.org.ORCID http://orcid.org/0000-0003-1529-3398
Cleveland Clinic Lerner College of Medicine · USJilin University · CN
Funding
Targeting Plasmacytoid Dendritic Cells to Treat Human MyelomaR01CA163881 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YI, QING · 2012 to 2016
$2.0MRole of MIF in myeloma bone homing and drug responseR01CA211073 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI YI, QING · 2017 to 2021
$1.8MA novel T-cell subset able to kill relapsed cancersR01CA200539 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI YI, QING · 2016 to 2020
$1.8MTh9 cells as a promising effector T-cell subset for cancer therapyR00CA190910 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LU, YONG · 2017 to 2019
$747kTh9 cells as a promising effector T-cell subset for cancer therapyK99CA190910 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LU, YONG · 2015 to 2016
$185kNCI NIH HHS K99 CA190910NCI NIH HHS R00 CA190910NCI NIH HHS R01 CA163881NCI NIH HHS R01 CA200539NCI NIH HHS R01 CA211073
Abstract
Tumor-specific CD4
Indexed as
AcetylationAnimalsCD4-Positive T-LymphocytesCell DifferentiationCells, CulturedCytokinesForkhead Box Protein O1Forkhead Transcription FactorsGene Expression RegulationHistonesHumansInterleukin-7Interleukin-9Lung NeoplasmsLymphocyte ActivationMelanomaCytokinesForkhead Box Protein O1Forkhead Transcription FactorsFoxo1 protein, mouseFoxp1 protein, mouseHistonesInterleukin-7Interleukin-9Repressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.